Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell?Defense World · Oct 15, 2026
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewsWire · Oct 8, 2026
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCGlobeNewsWire · Oct 8, 2026
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing RequirementsGlobeNewsWire · Sep 30, 2026
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.GlobeNewsWire · Jul 29, 2026Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$2.53 | -$1.52 | Beat |
| May 15, 2026 | -$2.64 | -$1.61 | Beat |
| Mar 31, 2026 | -$1.50 | -$1.20 | Beat |
| Nov 14, 2025 | -$3.04 | -$1.50 | Beat |
| Aug 14, 2025 | -$2.50 | -$1.50 | Beat |
| May 14, 2025 | -$0.05 | -$3.21 | Miss |